Navigation Links
Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009
Date:2/17/2009

SAN DIEGO, Feb. 17 /PRNewswire/ -- Tracon Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that its three clinical stage cancer therapeutics (TRC105, TRC102, and TRC093) will be presented at the 100th Annual Meeting of the American Association for Cancer Research this April 18-22 in Denver, Colorado. "Each program targets a unique pathway with the potential for broad application to a wide variety of cancer types, and we are pleased that all three will be presented at this year's meeting" explained Bryan Leigh, MD, Chief Medical Officer at Tracon Pharmaceuticals.

TRC105 is a chimeric IgG1 monoclonal antibody that binds CD105, a membrane receptor required for angiogenesis. By inhibiting new blood vessel formation, the antibody is expected to have activity against a wide variety of solid tumors that rely on angiogenesis to grow and metastasize. Clinical data from a phase 1 first-in-human study of TRC105 therapy for advanced cancer was recently presented at the 11th International Symposium on Anti-Angiogenic Agents in San Diego, CA by Michael S. Gordon, MD (Premiere Oncology, Scottsdale, AZ). TRC105 may also be a useful therapy for age-related macular degeneration, the most common cause of blindness in people over the age of 50.

TRC102 is a small molecule inhibitor of base excision repair that improves the therapeutic index of commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an i.v. agent in combination with temozolomide (Temodar(R)).

TRC093 is a humanized IgG1 monoclonal antibody that inhibits angiogenesis, tumor growth, and metastasis by binding cleaved collagen in the extracellular matrix of cancers. This antibody is expected to address multiple solid tumor types and may also be developed for age-relate
'/>"/>

SOURCE Tracon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. The Effects of Probiotics on the Aging Digestive Tract to be Presented at Nutracon 2009
2. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
3. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
4. Union Springs Pharmaceuticals Introduces New, More Effective Respirator
5. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2008 Financial Results
6. DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
7. Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
8. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
9. Biotest Pharmaceuticals Corporation Acquires Santa Fe, New Mexico Plasmapheresis Center
10. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
11. Par Pharmaceutical Announces Outcome of the Litigation With Pentech Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... Church, VA (PRWEB) , ... August 30, 2015 ... ... **FDAnews Webinar**, Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... much more than a simple digital handwritten signature. , Clinical trial ...
(Date:8/29/2015)... ... , ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, ... the chiropractic field in the military. All too often VA hospitals treat patients with ... available to the VA program over a decade ago, the reality is that only ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... with stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed ... to improve treatment outcomes. This localized treatment seems to address the symptoms ...
(Date:8/28/2015)... ... August 28, 2015 , ... An online provider of CPAP machines, masks, supplies, ... CPAP equipment more affordable by offering shipping at no cost to you, directly to ... orders of any size. My Cpap Store is located in Las Vegas, Nevada. , ...
(Date:8/28/2015)... , ... August 28, 2015 , ... For Dallas, the ... taking part with their subsidiary USPI Tenet Health. , The American Heart Association hosts ... disease and stroke. They believe that together, a difference can be made. Walkers can ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2
... ... technology for sales assessment testing helps employers customize a sales ability test for Customer ... 10 free sales ability tests , ... (PRWEB) May 13, 2010 -- Good sales people and good customer ...
... 13, 2010) -- A national summit of medical professionals ... of consensus scan techniques as a way of addressing ... common medical imaging procedure that uses X-rays to show ... together some of the world,s leading experts in CT ...
... Michigan survey, most said they,d try to get to ER on ... aren,t familiar with the symptoms of a stroke and most who ... stroke occurred, a new survey finds. , "If you know the ... them, that doesn,t do you much good," said study author Chris ...
... ... Diversified’s Information Lifecycle Solutions in the Financial, Insurance & Healthcare Industries, , ... Scranton, Pa. ... of document and information lifecycle solutions, announced today that it has formed a ...
... new study led by researchers from Mayo Clinic in ... patients with non-Hodgkin,s lymphoma who smoked, consumed alcohol or ... survival, compared to patients who did not have these ... and demographic factors, and also when considering only deaths ...
... for males tying the knot with younger females, study found , ... to nine years their junior could be upping their odds of ... significantly younger guy raises a woman,s risk of death by 20 ... of Demography . , Not that marrying much older men ...
Cached Medicine News:Health News:Top Sales Ability Test and Sales Assessment Test Does Customer Service Skills Assessment Testing Too 2Health News:Top Sales Ability Test and Sales Assessment Test Does Customer Service Skills Assessment Testing Too 3Health News:Top Sales Ability Test and Sales Assessment Test Does Customer Service Skills Assessment Testing Too 4Health News:Symposium focuses on patient safety in CT scanning 2Health News:Symposium focuses on patient safety in CT scanning 3Health News:Too Many Wouldn't Call 911 If Stroke Hit 2Health News:Too Many Wouldn't Call 911 If Stroke Hit 3Health News:Diversified Information Technologies and Sanava, Inc. Form Strategic Alliance 2Health News:Diversified Information Technologies and Sanava, Inc. Form Strategic Alliance 3Health News:Diversified Information Technologies and Sanava, Inc. Form Strategic Alliance 4Health News:Lifestyle factors significantly impact survival of non-Hodgkin's lymphoma patients, study finds 2Health News:Lifestyle factors significantly impact survival of non-Hodgkin's lymphoma patients, study finds 3Health News:Lifestyle factors significantly impact survival of non-Hodgkin's lymphoma patients, study finds 4Health News:Women Who Marry Younger Men May Die Earlier 2
(Date:8/28/2015)... JACKSONVILLE, Fla. , Aug. 28, 2015  With ... reaching deadlier heights, Jacksonville ... Philip Hemphill is helping to explain why ... Fentanyl is approximately 40 to 50 times more potent ... by recreational users as heroin, the risk of death ...
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., a ... cancer, today announced the filing of a registration statement ... Commission (SEC) relating to a proposed initial public offering ... be offered and the price range for the offering ... its common stock under the symbol "CTMX" on the ...
(Date:8/28/2015)... 28, 2015 Research ... addition of the "Investigation Report on China,s ... Originally discovered by Welfide (Mitsubishi Tanabe ... Ltd) as an inflammatory drug, pranoprofen was later ... Ltd under the trade name of pranopulin for ...
Breaking Medicine Technology:Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 2
... Calif., Feb. 28, 2011 Varian Medical Systems, Inc. (NYSE: ... into a new agreement with Bank of America N.A. to ... share repurchase program.   Under the accelerated repurchase ... N.A. and receive approximately 3.5 million shares, or 85% of ...
... 2011 S*BIO Pte Ltd today announced that its ... (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive ... in vitro data on SB2343 were presented ... on Targeting PI3K/mTOR Signaling in Cancer held in San ...
Cached Medicine Technology:Varian Medical Systems Announces New $280 Million Accelerated Stock Repurchase 2Varian Medical Systems Announces New $280 Million Accelerated Stock Repurchase 3S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 2S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 3
... x 7.5 x 80 mm. Storz ... line designed by Harvey A. Lincoff, ... closed cell sponge which is non-toxic ... rounded edges to minimize scleral intrusion. ...
... 7.5 x 80 mm. Storz offers ... designed by Harvey A. Lincoff, M.D. ... cell sponge which is non-toxic and ... edges to minimize scleral intrusion. These ...
Thin silicone pad implant. Indications: For closing scleral ruptures. Overall length: 7.8 mm....
... Size: 5.0 x 2.5 x 80 mm. Half ... by Harvey A. Lincoff, M.D. has been modified ... design. The material is a closed cell sponge ... with rounded edges to minimize scleral intrusion. These ...
Medicine Products: